UnitedHealth CEO leaves abruptly, company pulls forecast as shares sink
Published -nc- - Modified on 05/14/2025 at 02:26 am IST

|
Market Closed -
Other stock markets
|
After hours 03:31:51 am | |||
| 282.34 USD | -0.99% |
|
282.08 | -0.09% |
| 02:58pm | Wolfe Research Adjusts Price Target on UnitedHealth to $350 From $400, Maintains Outperform Rating | MT |
| 09/03 | Investors Confront Stagflation Risk |
Published -nc- - Modified on 05/14/2025 at 02:26 am IST


Andrew Philip Witty is a British businessperson who has been the head of 8 different companies. Presently, Sir Witty holds the position of Chief Executive Officer & Director at UnitedHealth Group, Inc. and Chief Executive Officer for InGensa, Inc. (a subsidiary of UnitedHealth Group, Inc.) and Chief Executive Officer of GlaxoSmithKline, Inc. Sir Witty is also on the board of Synthego Corp., Pharmaceutical Research & Manufacturers of America and G1 Therapeutics, Inc. and Chancellor at The University of Nottingham and Member of Business Council for Britain. In his past career Andrew Philip Witty held the position of Chief Executive Officer & Executive Director at GlaxoSmithKline Plc Chief Executive Officer & Director at Genelabs Technologies, Inc. Chief Executive Officer & Director at GlaxoSmithKline Australia Pty Ltd. Managing Director at GlaxoSmithKline South Africa (Pty) Ltd. Director-Pharmacy & Distribution at Glaxo Holdings Plc, Senior Vice President-Asia Pacific at GlaxoSmithKline Pte Ltd. Area Director at Glaxo Wellcome South Africa Pty Ltd. and Vice President & General Manager-Marketing at Glaxo Wellcome, Inc. (which are all subsidiaries of GlaxoSmithKline Plc), Director-Business Development at Biocompatibles International Ltd., Member-International Advisory Council at Singapore Economic Development Board and Chairman for European Federation of Pharmaceutical Industries & Assns. Sir Witty received an undergraduate degree from The University of Nottingham.
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Select your edition
All financial news and data tailored to specific country editions